Results 341 to 350 of about 225,115 (385)
Some of the next articles are maybe not open access.
Phosphodiesterase 4 inhibitors
Journal of the American Academy of Dermatology, 2018Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema Zebda, Amy S. Paller
openaire +4 more sources
Xanthines and Phosphodiesterase Inhibitors
Handbook of Experimental Pharmacology, 2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
Clive P. Page, Domenico Spina
openaire +3 more sources
Phosphodiesterase in Psoriasis [PDF]
British Journal of Dermatology, 1969 SUMMARY. . Phosphodiesterase activity was determined by a fluorometric method using thymidine-5′-3–0-methoxy fluorescein phosphate as a substrate, in blood serum, finger-blood, normal skin, foreskin and psoriatic skin. Higher enzyme activity was found in psoriasis both in blood-serum and finger-blood in comparison with normal controls ...
F. Zaeuba +2 more
openaire +2 more sources
Advances in the development of phosphodiesterase-4 inhibitors.
Journal of Medicinal Chemistry, 2020Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the
Ting Peng +4 more
semanticscholar +1 more source
Electrophysiology of phosphodiesterase inhibitors
The American Journal of Cardiology, 1989Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
Richard A. Goldstein +1 more
openaire +3 more sources
2003
Publisher Summary This chapter gives an overview on cyclic GMP-specific cGMP-binding phosphodiesterase (PDE5), a class I mammalian PDE with a catalytic site that specifically hydrolyzes the phosphodiester bond of cGMP and an allosteric site that binds cGMP with high specificity.
Sharron H. Francis, Jackie D. Corbin
openaire +2 more sources
Publisher Summary This chapter gives an overview on cyclic GMP-specific cGMP-binding phosphodiesterase (PDE5), a class I mammalian PDE with a catalytic site that specifically hydrolyzes the phosphodiester bond of cGMP and an allosteric site that binds cGMP with high specificity.
Sharron H. Francis, Jackie D. Corbin
openaire +2 more sources
Phosphodiesterase inhibitors and the eye
Clinical & Experimental Ophthalmology, 2009AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M. Kerr, Helen V. Danesh-Meyer
openaire +2 more sources
Lung Phosphodiesterase Isoenzymes
1993The distinct phosphodiesterase isoenzyme activities in guinea-pig lung were identified and characterised. We demonstrate that protein kinase A catalyses the activation of lung Type V cyclic GMP phosphodiesterase. This occurs via a marked change in the Vmax for cyclic GMP hydrolysis.
Pyne, N J, Burns, F
openaire +3 more sources